U.S. Markets open in 2 hrs 8 mins

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
248.10-1.94 (-0.78%)
At close: 4:00PM EDT
People also watch
CELGREGNGILDAMGNALXN
  • So AMGN misses earnings, fails a phase 3 safety study and barely goes down on either event. Biogen beats earnings, acquires a phase 3 start up and has dropped $45 in a month. Makes sense.
  • Would paying out a dividend help? I'd rather they acquire like they are doing, but the stock is complete garbage right now. It needs something to lift it.
  • There's many reason why BIIB is going down lately. Firstly as Morgan Stanley points it out there won't be buyouts, secondly and the most investors concerning about is a new MS drug that will eating away Biogen MS franchise and thirdly the Biotech sector cannot break out of the doldrums. But for Biogen the next earning report will give a clearer picture how much new drug takes its market share and how much royalty they get and their Spinraza drug sale progress. Biogen gave a great guidance for 2017 earnings which is more than $20 per share and they bested in the first quarter. A lot of Analysts still very bullish about Biogen but few are very skeptical. Next Earnings will clear this up. I think there are a lot of things going for Biogen in the long term (1 to 2 yrs) investors will be very well rewarded.
  • RALLLLLLLLLYYYYYYYYYYYY ..CHEAPEST BIOTECH HERE
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjcwNTc4fENoaWxkSUQ9Mzc3ODc0fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • why it continue down, any good suggestion for what should I do, thanks
  • In all seriousness, where do you guys think the bottom is? Last couple of times it tanked, it went all the way to $225. Goes through all support levels like nobodies business. I think this has been down every day since earnings except maybe 3! Aside from the one day that it went up $4 on the purchase, the other 2 days were < $1 following long losing streaks.
  • So we roughly bounced off of 275 4 times in the past 2 yrs, we sliced through that no problem. Did a couple small bounces off 245... bounced off of 225 *hard* and ran up to 330 and in 1 month... then went back to tanking. This stock has had long periods of tanking... but there have always been bounces along the way. Never seen such a flat line down.
  • I'm beginning to understand why our grandparents stashed money under their mattresses!
  • good news finally but maybe a buck or two. this dog is hurting.
  • pfe, you're close by. offer 325 and take these idiots out.
  • looking at the 1yr price trend, seems the support at 250 was expected yet the overall trend is in a tight channel downwards. Any ideas when this might stop? are there any potential catalysts before next year Alzheimer's ? ( itself a long shot) or is my beloved biib becoming a gild?
  • yeah,went from 251 to 260. I should have bailed.
  • Appeals court holds lower court's dismissal of investors suit against Biogen. A bit of good news is always welcome.
  • this POS better hold 250 or were in deep sheet.
  • Biogen didn't hold above $259 but that was largely market forces rather than the stock itself .. Technically and on daily frame, $255 is an important threshold to establish now to be followed by $260 but more critical is to hold above $268-270 price ..

    The Money Flow index, crucial indicator, is showing "signs" that the worst is behind us and its well supported by both Wm%R and CCI .. MACD & Full STO still didn't confirm positive signals although seem close
  • On the daily frame, all key Tech. Indicators including CCI, Wm%R, RSI and both Fast & Slow Stochastic are giving entry point around current price +/- &3 for BIIB .. Yet the MFI & MACD are not there exactly yet although close .. unless something fundamental happens i think at or around $250 is excellent price
  • Why is BIIB dropping like its hot? I thought 250 was bottom?
  • almost 260. can't hold the gains
  • this,junk is dead
  • 7:51 AM EDT, 05/15/2017 (MT Newswires) -- Biogen (BIIB) said pre-market Monday it completed an asset purchase of Remedy Pharmaceuticals' phase 3 candidate, CIRARA. The target indication for CIRARA is large hemispheric infarction, a severe form of ischemic stroke.
    Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments.